The COVID-19 pandemic has altered the world and reiterated the
perpetual need for the development of effective strategies for the
prevention and treatment of infectious diseases. While globally
prevalent infectious diseases receive extensive attention in terms
of drug development and delivery, the neglected and/or emerging
infectious diseases that affect developing countries are often
overlooked. Additionally, the therapeutic efficacy of existing
anti-infective agents is often limited due to sub-optimal
biopharmaceutical properties, sub-therapeutic levels of the drugs
at the infection site due to various physiological barriers, the
expulsion of the drug by efflux transporters, and the emergence of
drug-resistant strains. From the commercialization of AmBisome® to
the emergency authorization of mRNA-based vaccines, nanotechnology
has played a vital role in the prevention and treatment of
infectious diseases. More importantly, nanotechnology has enabled
the effective utilization of existing armamentarium against
infectious diseases leading to improved therapeutic outcomes with a
concomitant reduction in the side effects associated with
anti-infective agents. In particular, nanotechnology can bring
about a paradigm shift in the management of neglected and emerging
infectious diseases and may compensate for the lack of drug
discovery efforts. While there are several books dedicated to
pharmaceutical and/or biomedical applications of nanotechnology or
nanotechnology for cancer therapy a comprehensive book focusing on
the prevention and/or treatment of viral, bacterial, fungal, and
parasitic infections is not available. This book addresses an unmet
need in pharmaceutical and medical education. This book provides a
comprehensive and up-to-date overview of the latest advancements in
nanomedicine, which show great potential for preventing and
treating infectious diseases. Covering a wide range of topics, it
explores various formulation strategies for combating microbial,
fungal, parasitic, and viral infections. The book emphasizes the
advantages of nano-scale vaccines over traditional ones and
discusses their production. It also examines feasible treatment
approaches for diseases like malaria, trypanosomiasis, candidiasis,
Hepatitis B, HIV, and the ongoing COVID-19 pandemic. Additionally,
it highlights the role of nano-adjuvants in vaccine development, as
well as the use of peptide antibiotics and pulmonary delivery of
drugs, which open up new possibilities in fighting infectious
diseases. Furthermore, the book explores the critical role of
nanomedicine in addressing veterinary parasitic infections. The
emergence of nanotechnology has led to novel strategies for
diagnosing, treating, and preventing parasitic infections in
animals. In summary, this book offers a comprehensive description
of clinically viable and investigational nanotechnology-enabled
medicines (nanomedicines) for the prevention and treatment of
globally prevalent, neglected, and emerging infectious diseases.
General
Imprint: |
Springer International Publishing AG
|
Country of origin: |
Switzerland |
Series: |
AAPS Advances in the Pharmaceutical Sciences Series, 56 |
Release date: |
October 2023 |
Editors: |
Vandana B Patravale
• Abhijit Date
• Anil B Jindal
|
Dimensions: |
235 x 155mm (L x W) |
Pages: |
466 |
Edition: |
1st ed. 2023 |
ISBN-13: |
978-3-03-139019-7 |
Categories: |
Books
Promotions
|
LSN: |
3-03-139019-9 |
Barcode: |
9783031390197 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!